$19.730
-0.769 (-3.90%)Al cierre
Noticias de VOGX
Eventos de VOGX
Vogenx Initiates EMERGE Trial Evaluating Mizagliflozin
Vogenx announced the initiation of EMERGE, its Phase 2b clinical trial evaluating mizagliflozin for the treatment of post-bariatric hypoglycemia. There are currently no therapeutics approved by the U.S. FDA for the treatment of PBH. EMERGE is a randomized, placebo-controlled, double-blind, parallel-group Phase 2b study designed to enroll approximately 36 adults who underwent bariatric surgery more than 12 months prior and who experience recurrent reactive hypoglycemia. Following a three-week run-in period, eligible participants will be randomized to receive mizagliflozin 5 mg, mizagliflozin 10 mg or placebo, taken orally three times daily for 28 days. The study will evaluate the safety and tolerability of mizagliflozin and its ability to reduce hypoglycemia, with glucose monitored continuously throughout treatment. Primary endpoint is the number of combined Level 2 and Level 3 hypoglycemic events. The trial is expected to be conducted at approximately 10 sites in the United States.
Vogenx Appoints Richard Gorman as Chief Commercial Officer
Vogenx announced that Richard Gorman will join the Vogenx management team as Chief Commercial Officer, effective October 12, 2026. Concurrent with his joining the management team, Gorman, who has served as an independent member of the Vogenx Board of Directors since 2022, will resign as a member of the Board and its committees. Vogenx will conduct a search to identify a new independent director to join the Board.
Vogenx Appoints Ken Toombs as Independent Director
Vogenx announced the appointment of Ken Toombs to its Board of Directors. Mr. Toombs will serve as an independent director and as Chair of the Audit Committee. Toombs is a thirty-year veteran of the global professional services industry, most recently serving as CEO of PA Consulting.
Vogenx and Londian Wason Open Higher with Strong IPO Pricing
Vogenx and Londian Wason opened higher after upsized deals and high end pricing, underscoring still strong investor appetite for new listings.LATEST IPOS AND DIRECT LISTINGS:Vogenxopened on August 12 at $13. The clinical-stage biopharmaceutical company focused on development of therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism priced its initial public offering of 6.25M shares at $13.00 per share. The IPO priced at the high end of the $11.00-$13.00 range. All of the shares are being offered by Vogenx.Londian Wasonopened on August 12 at $26. The company priced 4.3M shares at $22.00. The deal size was increased to 4.3M shares from 3.8M shares of common stock and priced at the high-end of the $20.00-$22.00 range. Londian Wason says it was the world's largest supplier of lithium-ion battery copper foil in terms of sales volume in 2025, holding a global market share of 7.6%.PERFORMANCE:Prices as of 10:15 am ET on Monday, August 17Vogenx – up more than 6% at $15.68.UPCOMING IPOS:Upcoming IPO and direct listings expected include EvoAirand Inspire Brands.Clickto see upcoming IPO calendar on TipRanks.EvoAir Holdingshas filed for a firm commitment initial public offering of shares of common stock and anticipates that the initial public offering price of shares will be between $4.00 and $5.00 per share. The company said it will apply to list its common stock on the Nasdaq Capital Market under the symbol "EVOH". EvoAir Group is an emerging green technology focusing on eco-friendly heating, ventilation, air conditioning inventions and efforts in the environmental, social and governance initiatives. The Group is principally engaged in the research and development, manufacturing, sale and marketing of HVAC products for residential, commercial and industrial uses.Inspire Brandsannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
Vogenx, Inc. Trading Halted Due to Volatility
Vogenx, Inc. trading halted, volatility trading pause
Artículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.